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Abstract
Introduction
Opioids are one of the most important and effective drug classes in pain medicine with a key
role in most medical fields. The increase of opioid prescription over time has led to higher
numbers of prescription opioid misuse, abuse and opioid-related deaths in most developed
OECD (Organisation for Economic Co-operation and Development) countries around the
world. Whilst reliable data on the prevalence of opioid treatment is accessible for many
countries, data on Germany specifically is still scarce. Considering Germany being the larg-
est country in the European Union, the lack of evidence-based strategies from long-term
studies is crucial. The aim of this work is to review and summarise relevant published litera-
ture on the prevalence of opioid prescription in Germany to adequately inform health policy
strategies.
Methods
A systematic review of the epidemiology of opioid prescription in Germany was conducted,
searching PubMed and Web of Science. Eligibility criteria were defined prior to conducting
the search. Literature concerning Germany, published in English and German was included
and the search was replicated by three independent researchers. Two levels of screening
were employed. Disagreement was resolved by face-to-face discussion, leading to a con-
sensus judgement.
Results
Our electronic search yielded 735 articles. Reviewing titles and abstracts yielded 19 relevant
articles. Three authors examined each article’s full text more closely and determined that
twelve papers should be included. Of the twelve identified studies—with publication dates
ranging from 1985 to 2016—six were retrospective cross-sectional studies and six were ret-
rospective repeated-measures cross-sectional studies. Sample sizes ranged from 92,842
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to� 11,000,000 participants. Data sources of included studies showed vast heterogeneity.
The reviewed literature suggested an increase in the number of patients with opioid pre-
scriptions and defined daily doses of opioids per recipient in Germany over time. The major-
ity of opioid prescriptions was used for patients with non-cancer pain. Opioid use was more
common in older people, women and in the north of Germany. Fentanyl was shown to be
the most prescribed strong opioid in outpatient settings in Germany, despite not being the
first-line choice for chronic pain conditions. All data published before 2000—but none of the
more recent studies—suggested an insufficient treatment of pain using opioids. There were
no signs for a current opioid epidemic in Germany.
Conclusions
Despite some limitations of the review and the heterogeneity of studies, it can be stated that
the number of opioid prescriptions overall as well as the number of people receiving opioid
treatment have increased over time. Most prescriptions were found to be for strong opioids
and patients with non-cancer pain. Even though patterns of opioid prescription follow trends
observed in other developed countries, there are no signs of an opioid epidemic in Germany.
Therefore, this review could currently not find a need for urgent health policy interventions
regarding opioid prescription practices. However, critical gaps in the literature remain and
more research is needed to make more reliable judgements.
Introduction
Opioids are one of the most important and effective drug classes in pain treatment [1–4], with
a key role in modern anaesthesia, palliative care, emergency medicine and specialised pain
management [3, 5, 6]. In 2016, North America, Oceania and Western Europe reported an aver-
age consumption of over 10,000 defined daily doses (DDD) of opioid analgesics [7]. Opioids
pose a serious risk of addiction and abuse. Their long-term use still remains one of the biggest
concerns about opioid treatment, since higher doses and prolonged continuous use increase
the probability of adverse effects, habituation and dependence [8–12]. What was seen by some
as the unmet need for pain management in chronic pain patients, caused by reluctance to use
opioids considering their addiction potential [11, 13–15], has recently become an upsurge in
numbers of opioid prescriptions through pharmaceutical market access strategies and policy-
making. This is affecting G20 (Group of 20) countries severely and especially so in chronic
non-cancer pain (CNCP) patients [12, 16–18]. The increase in opioid prescription over the
past decade has led to higher numbers of prescription opioid misuse, abuse and opioid-related
death cases in most developed OECD (Organisation for Economic Co-operation and Develop-
ment) countries around the world [16, 19]. For example, the Global Burden of Disease Study
showed a 22.3% increase in global opioid use disorder-related DALYs (disability-adjusted life
years) between 2005 and 2015 [20]. Drug use disorders ranked as the 8th most common cause
of premature death in the US in 2016 [21]. The Canadian government reported an increase of
81% in accidental deaths involving fentanyl or fentanyl analogues between 2016 and 2017 [22].
Hence, there has been a shift from under-treatment of pain observed in the second half of the
20th century, to an opioid crisis linked to over-prescription as part of pain management strate-
gies [23]. In the US, roughly 21–29% of patients with opioid prescriptions for chronic pain
misuse them and an estimated 4–6% of misusers eventually shift to heroin use [24–26]. In
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2013, it was reported that about 2.4% of Australians aged 14 or older had used opioids for
non-medical reasons at least once in their lives [27].
Whilst reliable data on the prevalence of opioid treatment is accessible for many countries,
data on Germany is specifically sparse, despite it being the largest national economy in Europe,
the fourth-largest by nominal GDP in the world, and fifth-largest by GDP (PPP) [28]. In 2017,
Germany accounted for 28% of the euro area economy according to the International Mone-
tary Fund, while having the largest population in the European Union (82 million people) [21,
28]. Consequently, and following the US and other developed economies, the opioid epidemic
has recently become an issue of public debate, with concerns Germany might be following
trends of other developed countries towards an opioid crisis [29, 30]. According to the UN’s
2017 report on narcotic drug use, Germany has the second highest opioid consumption of the
20 most populous countries in the world (28,842 DDD/1 million people/day; based on sales
data) [7].
Pain medication prescription in Germany is based on national guidelines published by the
AWMF (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V.).
A guideline for the long-term use of opioids in the treatment (LTOT) of non-tumour pain was
published in 2009 [31]. However, there is a multitude of guidelines concerning opioid prescrip-
tion in different healthcare settings (e.g. palliative care, chronic-cancer pain, pain management
for children) in Germany. As a result, prescribing opioids according to the appropriate guide-
line in place remains difficult. Thus, it is crucial to understand the current prevalence of opioid
prescription in Germany to avoid a further rise of opioid misuse and opioid-related disorders.
So far, the only effective approach to this national (and international) public health problem has
been to design primary population level data collection strategies to analyse current and past
trends in order to develop sufficient long-term prevention strategies.
Aim
Considering the lack of evidence-based strategies from long-term studies on the German pop-
ulation in relation to the administration of opioids [14], the aim of this paper is to present
results of a systematic review of literature concerning opioid prescriptions among outpatients
in Germany. This study will assess the extent of opioid use for different health conditions,
describe populations treated with prescription opioids, and characterise prescription patterns
over time. Furthermore, it will use gathered information to provide recommendations for
health policy. The review will focus on prescription of all types of opioids.
Definition and classification of opioids
According to the World Federation of Societies of Anaesthesiologists, an opioid is “any natu-
rally occurring, semi-synthetic or synthetic compound that binds specifically to opioid recep-
tors and shares the properties of one or more of the naturally occurring endogenous opioids.”
Opiates are defined as “any naturally occurring opioid derived from opium (e.g. morphine)”
[32]. Opioids may be classified according to: (i) their analgesic potency, (ii) their origin and
(iii) their action at the opioid receptor (Table 1) [32, 33].
Opioid prescription laws and German guidelines for opioid therapy
Opioid prescription in Germany is tightly regulated by the Narcotic Drugs Prescription Ordi-
nance (Beta¨ubungsmittelverschreibungsverordnung, BtMVV) and by the German Narcotic
Drugs Act (Beta¨ubungsmittelgesetz, BtMG) which entered into force in 1992 [34].
The BtMVV gives detailed information on prescription rules (maximum quantities of opi-
oids prescribed within a timeframe, maximum amount of different opioids prescribed at once)
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[35]. In Germany, all opioids must be prescribed by a medical doctor, a veterinarian or a den-
tist [34]. All opioids—except Tramadol and Codeine (normal prescription only)—require spe-
cial narcotic prescriptions known as “BtM”-prescriptions [36].
Most opioid therapy regimens in Germany are based on the WHO guidelines for cancer
pain treatments published in 1986 and are therefore following the WHO analgesic ladder [37].
This applies for all cancer pain treatments as well as for treatment of acute pain conditions.
In 2008, a guideline for long-term treatment of CNCP was published. The guideline estab-
lished general indications and contraindications for opioid analgesic treatment for four weeks
or longer. It also comments on how the treatment should be conducted, basing these recom-
mendations on detailed analyses of the evidence and structured consensus formation [38].
Methods
Eligibility criteria
An important aspect when talking about drug therapy is the duration of treatment, since medi-
cal professionals distinguish between chronic or long-term (> 3–6 months) and acute or
short-term (< 3–6 months) treatment [39]. Both, studies on chronic and acute pain manage-
ment were included in this review. Also, studies on pain management in cancer and non-can-
cer patients were reviewed respectively.
Although most adult hospital patients receive are given opioids at least once during their
hospital stay, no formal prescriptions are used. Instead, opioid use is recorded in so called opi-
oid books, which makes assessment of opioid users in inpatient settings difficult [35]. Hence,
this study focuses on outpatient settings only.
The following inclusion and exclusion criteria were established prior to the literature
search:
Table 1. Classification of opioids used in Germany. Adapted from Trivedi et al. [32].
Potency Origin Function
Strong
• Morphine (17.9%)�
• Pethidine
• Fentanyl (32.3%)
• Alfentanil
• Remifentanil
• Sufentanil
• Oxycodone (26.8%)
• Piritramide
• Hydromorphone (10.5%)
• Tapentadol (2.9%)
Intermediate
• Buprenorphine (8.2%)
• Nalbuphine
• Tillidine
Weak��
• Codeine
• Tramadol
Naturally occurring
• Morphine
• Codeine
• Papavarine
• Thebaine
Semisynthetic
• Diamorphine (Heroin)
• Dihydrocodeine
• Buprenorphine
• Oxycodone
• Hydromorphone
Synthetic
• Pethidine
• Fentanyl
• Alfentanil
• Sufentanil
• Methadone
• Levorphanol
• Piritramide
• Tapentadol
• Tillidine
Pure agonists
• Morphine
• Fentanyl
• Alfentanil
• Remifentanil
• Sufentanil
• Oxycodone
• Piritramide
• Hydromorphone
• Tapentadol
• Tillidine
Partial agonist
• Buprenorphine
Agonists-antagonists
• Nalbuphine
Pure Antagonists
• Naloxone
• Naltrexone
� Numbers in brackets present the market share of the respective opioid according to packages sold for patients of statutory health insurances in Germany in 2011 (1.4%
of market share devoted to “other opioids”). (Kieble M., 2012)
�� Codeine and Tramadol do not require a special opioid prescription but can be obtained with a standard prescription.
https://doi.org/10.1371/journal.pone.0221153.t001
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• Medical setting: Only studies analysing data on prescription of opioids in outpatient settings
were included.
• Participants: Only studies analysing data on use of prescription opioids among adults,
regardless the underlying cause of the initial treatment, were included.
• Class of opioids: Studies analysing data on general opioid prescription or prescription of a
certain class of opioids were included.
Two additional a priori exclusion criteria were established, excluding studies focused on
children or adolescents, and those strictly referring to one specific opioid only (e.g. tramadol,
fentanyl). Furthermore, language as a study reporting attribute was also defined as an inclu-
sion/exclusion criterion (Table 2).
Literature search strategy
A systematic literature search was carried out on 21 November 2018 using PubMed and Web
of Science as primary data sources (Table 3 and Fig 1). Studies were selected upon meeting
predefined eligibility criteria (Table 2). Additionally, a web search engine (Google.com) was
employed to also include grey literature. Two levels of screening by three independent
researchers (B. Rosner, J. Neicun, J. Yang) were used on all citations. Our electronic search
yielded 735 articles. We reviewed titles and abstracts and excluded all articles that clearly did
not meet our inclusion criteria. This process yielded 19 articles, which were retrieved for more
thorough investigation in a second step. In-depth examination of the articles’ titles, abstracts
and—if needed—full texts was conducted by all three investigators, resulting in a final selec-
tion of 12 articles. At all stages of the selection process, disagreements between reviewers were
resolved by face-to-face discussion, eventually leading to a consensus judgement.
Due to the small number of included studies and the heterogeneity in study methodology,
the appropriateness of a meta-analysis had to be critically questioned and therefore, was not
included as part of this study.
Quality assessment
The quality of studies was assessed using the EPHPP (Effective Public Health Practice Project)
quality assessment tool for quantitative studies (S1 Table). The tool generates a total quality
score between one (strong) and three (weak) based on six sub-scores, assessing components of
internal and external validity.
Only three of the studies were awarded one point and therefore a strong rating. One study
was given moderate rating and eight were rated weak. This was mainly due to assumed selection
bias inherent to the nature of the data source (i.e. statutory health insurance that does not
Table 2. Inclusion and exclusion criteria for study selection.
Inclusion criteria Exclusion criteria
1. Full-text accessible at University of Cambridge
2. Language: English & German
3. Geographic area: Germany
4. Epidemiological data stating prevalence and/or
incidence of outpatient opioid prescription
5. Studies on general Opioid prescription/ prescription of
certain groups of opioids
1. Full-text not accessible at University of Cambridge
2. Languages other than English or German
3. Studies conducted in other German-speaking
countries
4. Studies focused on children or adolescents
5. Studies strictly referring to one specific opioid (e.g.
tramadol, fentanyl)
6. Studies solely referring to hospital opioid use
7. Studies (reviews) exclusively reporting results from
papers already included in the review
https://doi.org/10.1371/journal.pone.0221153.t002
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account for privately insured patients, private prescriptions and patients of other insurances,
patients changing health insurance). Thus, no credible inferences about the entire German pop-
ulation may be drawn from these papers. Likewise, no validity and reliability assessment for
data collection tools could be performed. As a result, four of the included cross-sectional studies
were awarded moderate component ratings for study design, and eight were rated weak.
Table 3. Search terms used in database search.
Database Search Strategy
PubMed 1. prescription [MeSH] OR prescription� OR prescrib�
AND
2. analgesics, opioid [MeSH] OR alkaloids, opiate [MeSH] OR opioid� OR opiate�
AND
3. germany [MeSH] OR german�
No filters used.
Web of Science 1. prescription� OR prescrib�
AND
2. Opioid� OR opiate� OR sedative� OR analgesic�
AND
3. german�
No filters used.
https://doi.org/10.1371/journal.pone.0221153.t003
Fig 1. Literature search strategy.
https://doi.org/10.1371/journal.pone.0221153.g001
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Overall, the evidence base was rated as low. However, the applied tool might not be ideal
for rating the quality of studies on secondary data such as insurance claims data and medical
records since some of the assessed components seem to be inappropriate (e.g. study design,
data collection methods or blinding).
Results
Twelve studies were found eligible for inclusion in this review (Table 4) with the search for
grey literature not revealing any additional relevant data. The agreement percentage between
raters was substantial at 83.3% (Cohen’s kappa = 0.79). Publication dates ranged from 1985 to
2016, six were retrospective cross-sectional studies [8, 40–44] and six were retrospective
repeated-measures cross-sectional studies [13–15, 45–47]. The six studies including national
data on Germany did not analyse data from the same time period. Thus, no data overlap hap-
pened. Among the five studies analysing data from overlapping periods, two used data from
different sources [14, 15], one did not give details of its data source [41] and two may have pre-
sented some temporal/geographical overlapping [13, 45]. However, this overlap was consid-
ered to broaden the evidence base while bringing validity to the results, so both studies were
included in the review respectively.
Sample sizes differed between 92,842 and� 11,000,000. All reviewed studies used second-
ary data as their main data source: eight studies used health insurance claims data [8, 13, 14,
40, 41, 44, 45, 47], one used prescription data from a pharmacy computing centre [15], one
from a disease analyser database [43], one from computerised patient records [42], and one
from mixed sources (clinical and market research) [46]. Among the eight publications using
health insurance claims records as data source, three obtained their data from BARMER GEK
[8, 14, 40], four from regional branches of the AOK [13, 44, 45, 47], and one did not state the
name of the statutory health insurance [41].
Six studies investigated the prevalence of opioid use regardless of treatment or opioid class
[13–15, 41, 43, 45]. Four studies specifically researched the prevalence of treatment with strong
opioids [40, 44, 46, 47]. Marschall et al. [8] focused on the prevalence of opioid use among
long-term treatment for chronic non-cancer pain patients, while Zenz et al. [42] solely investi-
gated patients with malignant diagnoses (cancer).
Prevalence
All studies used period prevalence as their primary outcome measure, defined as the propor-
tion of a population using a drug within a certain time period (Fig 2 and Table 5) [48]. Six
studies reported the prevalence for patients with any opioid prescriptions within their samples
ranging from 0.54% to 5.7% [13–15, 41, 43, 45]. One study calculated the prevalence of LTOT
prescriptions for CNCP among all insureds at 1.3% [8]. Four papers reported the prevalence
for patients with prescriptions for strong opioids between 0.057% and 1.39% [40, 44, 46, 47].
Zenz et al. [42] calculated in 1995 that 1.9% of cancer patients received strong opioids.
Age and sex
Ten studies did not state an age group for participants included in their studies. Two studies
reported a mean age between 43.9 and 46.3 years [13, 45]. Two papers provided sub-analyses
for opioid prescription in specific age groups [8, 15]. Six of the included studies did not pro-
vide any gender-specific characteristics of prescriptions [15, 41, 42, 44, 46, 47]. Jacob et al. [43]
did not analyse differences in prevalence of opioid prescription between males and females but
did provide the prevalence of patients with pain medication prescriptions separately for males
(28.9%) and females (30.3%). One study estimated that women are less likely than men to
Opioid prescription patterns in Germany
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Table 4. Summary of studies included in the systematic review.
# Reference Journal Year Region Age
Range
(years)
Total # of
patients
Study
period
Type of data / Primary
data source
Study type Descriptive
measures reported
in studies
1 Buth et al.
[15]
Bundesgesundheitsblatt-
Gesundheitsforschung-
Gesundheitsschutz
2017 Schleswig-
Holstein,
Hamburg,
Bremen,
Nieder-
sachsen
Not
given
�
11,000,000
2005
to
2011
Prescription data / North
German Pharmacy
Computing Centre
(Norddeutsches Apo-
thekenrechenzentrum,
NARZ)
Retrospective
repeated
measures
cross-sectional
study
Prevalence of
patients with
opioid
prescriptions
(subgroups
analysis of age
groups, mean
duration of
treatment/age
groups),
prevalence of
LTOT, mean
DDD/patient
2 Hoer et al.
[41]
Schmerz 2008 Germany Not
given
1,534,034 2000
to
2003
Insurance claims data /
Statutory health insurance
in Germany
Retrospective
cross-sectional
study
Prevalence of
patients with
opioid
prescriptions
3 Hoffmann
et al. [40]
Schmerz 2012 Germany Not
given
9,100,000 2011 Insurance claims data /
BARMER GEK
Retrospective
cross-sectional
study
Strong opioids
only: Prevalence of
patients with
opioid
prescriptions,
DDD/user
(subgroup analysis
for different
opioids)
4 Ihle et al.
[45]
Pharmacoepidemiology
and Drug Safety
2012 Hesse Not
given,
mean
age
43.9
(2000)
46.4
(2009)
326,598
(2000)
264,982
(2009)
2000
to
2009
Insurance claims data /
AOK Hesse
Retrospective
repeated
measures
cross-sectional
study
Prevalence of
patients with
opioid
prescriptions,
DDD/user, DDD
increase
5 Jacob et al.
[43]
Postgraduate Medicine 2018 Germany
(France)
(UK)
� 18 4,270,142 2016 Data from patient records /
Disease Analyzer database
(QuintilesIMS)
Retrospective
cross-sectional
study
Prevalence of
patients with pain
medicine
prescriptions
(opioids as
subgroup)
6 Lindena
et al. [46]
Schmerz 1996 Germany Not
given
1,218,436 1990
to
1996
Market share data,
prescription data, survey
data, data from a
questionnaire / Der
Deutsche Pharmamarkt
(DPM), Mediplus,
telephone survey,
questionnaire for clinicians
Retrospective
repeated
measures
cross-sectional
study
Strong opioids
only: Prevalence of
patients with
opioid
prescriptions
7 Marschall
et al. [8]
European Journal of Pain 2016 Germany Any
age
870,000 2012 Insurance claims data /
BARMER GEK
Retrospective
cross-sectional
study
LTOT for CNCP
only: Prevalence of
prescriptions for
CNCP among all
insureds,
Prevalence of
insureds with
high-dose opioids
among LTOT
(Continued)
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receive high-dose opioid prescriptions (adjusted OR 0.88; 95% CI: 0.77 to 0.99; p = 0.03) [8].
Werber et al. [14] solely described the peak age of opioid usage being different for men (40–45
years) and women (45–50 years). No further details were given to underpin this conclusion
[14]. A sub-analysis for strong opioid use in 2011, provided by Hoffmann et al. [40], showed
that 70.9% of new users of fentanyl patches were women.
Ihle et al. [45] reported higher prevalence of opioid prescriptions for women both in 2000
(males: 2.68%; females: 3.90%) and 2009 (males: 3.67%; females: 5.23%). Schubert et al. [13]
showed higher prevalence of use of prescription opioids among women in all years observed.
The latter also compared prevalence by sex for two years (2000 and 2010) for different stages
of the WHO ladder. Again, prevalence was higher for women within all strata [13].
Trends over time
Eight studies analysed prevalence of opioid prescription for a period longer than one year [13–
15, 41, 42, 45–47]. Five of these studies analysed repeated measures and reported a slight
increase in prevalence over time [13–15, 45, 47]. Despite reporting results for a study period of
four years, three studies [41, 42, 46] only gave one overall estimate for opioid prescription
prevalence (0.1%; 1.9%; 0.54% respectively). The biggest increase in prescription prevalence
was reported by Schubert et al. (+37%) [13].
Four studies calculated the prescription prevalence for one year only, ranging from 0.059%
(strong opioids only) in 1990 to 1.6% in 2016 [8, 40, 43, 44] (Fig 3).
Table 4. (Continued)
# Reference Journal Year Region Age
Range
(years)
Total # of
patients
Study
period
Type of data / Primary
data source
Study type Descriptive
measures reported
in studies
8 Schubert
et al. [13]
Deutsches A¨rzteblatt
International
2013 Hesse Not
given,
mean
age
43.9
(2000)
46.3
(2010)
326,554
(2000)
265,213
(2010)
2000
to
2010
Insurance claims data /
AOK Hesse
Retrospective
repeated
measures
cross-sectional
study
Prevalence of
patients with
opioid
prescriptions,
DDD/user, DDD
increase
9 Sorge et al.
[47]
Schmerz 1990 Hannover Not
given
322,467
(1985)
325,506
(1988)
1985
&
1988
Insurance claims data /
AOK Hannover
Retrospective
repeated
measures
cross-sectional
study
Strong opioids
only: Prevalence of
patients with
opioid
prescriptions, total
DDD Germany
10 Werber
et al. [14]
Pain Physician 2015 Germany Not
given,
mean
age
42.2
6,800,000 2006
to
2010
Insurance claims data /
BARMER GEK
Retrospective
repeated
measures
cross-sectional
study
Prevalence of
patients with
opioid
prescriptions, total
DDD CNCP &
CCP
11 Willweber-
Strumpf
et al. [44]
Schmerz 1992 Bochum Not
given
92,842 1989
to
1990
Insurance claims data /
AOK Bochum
Retrospective
cross-sectional
study
Strong opioids
only: Prevalence of
patients with
opioid
prescriptions
12 Zenz et al.
[42]
Journal of Pain and
Symptom Management
1995 West
Germany
Not
given
1,104,435 1990
to
1993
Computerised patient
records data / 330 practices
in West Germany
Retrospective
cross-sectional
study
Strong opioids for
cancer pain only:
Prevalence of
patients with
opioid
prescriptions
https://doi.org/10.1371/journal.pone.0221153.t004
Opioid prescription patterns in Germany
PLOS ONE | https://doi.org/10.1371/journal.pone.0221153 August 28, 2019 9 / 20
Geographical differences
Fig 4 shows the geographical distribution of the included sample populations within Germany.
Six studies referred to the entirety of the German population [8, 14, 40, 41, 43, 46], one study
included data from West Germany only [42], two studies concerned the region of Hesse [13,
45] and one of Northern Germany [15]. Two studies were geographically focussed on the cities
of Hannover [47] and Bochum [44] respectively.
The only study reporting geographical patterns in (high-potency) opioid prescription
within Germany was conducted in 2011 by Hoffmann et al. (Fig 5) [40]. Significant regional
differences were found with regard to opioid prescription prevalence by state, ranging from
1.13% (Baden-Wu¨rttemberg) to 1.67% (Lower Saxony) [40]. Similar differences were found
with regard to opioid prescription quantities: smaller proportions were observed in the south
(157.7 and 145.9 DDD/100 insureds for Bavaria and Baden-Wu¨rttemberg respectively) com-
pared to the north (259.5 DDD/100 insureds in Lower Saxony and 240.5 DDD/100 insureds in
Mecklenburg-West Pomerania). Differences were even clearer when calculating numbers for
postcodes rather than for states, with prescription volumes ranging from 87.0 DDD/100
insureds to 304.8 DDD/100 insureds.
Diagnosis
A sub-analysis of underlying causes of opioid prescriptions was provided by seven of the stud-
ies [8, 13, 14, 44–47]. All seven studies distinguished between prescriptions for cancer and
non-cancer pain. Five studies solely reported the fraction of all opioid prescriptions for every
group [13, 44–47]. Sorge et al. and Willweber-Strumpf et al. [44, 47] reported significantly
Fig 2. Prevalence of opioid prescription by opioid class included in study.
https://doi.org/10.1371/journal.pone.0221153.g002
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higher numbers of people with cancer diagnoses receiving opioid prescriptions in the late 80s,
whereas Lindena et al., Ihle et al. and Schubert et al. [13, 45, 46] found that the majority of
patients with opioid prescriptions did not have a malignant diagnosis (Fig 6).
Ihle et al. and Schubert et al. [13, 45] analysed opioids of different analgesic potency, and
how treatment with each of them differed between cancer and non-cancer patients [13, 45].
Werber et al. [14] subdivided opioid treatment for cancer and non-cancer patients by strong
and mild opioids [14]. They found that in 2006, 4.44% and 0.64% of all insureds received treat-
ment with mild opioids for non-cancer and cancer conditions respectively. The numbers
decreased for non-cancer patients to 4.21% and increased for tumour patients to 0.73% in
2009. Furthermore, they reported that—for mild opioids—most prescriptions in 2010 were
issued for back pain (23.4%), spondylosis (9.3%) and gonarthrosis (8.5%). For strong opioids,
most frequent diagnoses in 2010 were back pain (18.0%), unspecific pain (15.1%) and
Table 5. Comparison of descriptive measures.
# Reference Patients with
opioid prescription
(%)
Mean duration of
treatment (days)
Prevalence of LTOT among
patients with opioid
prescription (%)
DDD/user Mean DD
of LTOT
(mg)
Treatment for
CNCP/CCP (%)
Additional measures
1 Buth et al.
[15]
5.4 (2006)– 5.7
(2010)
107 (2006)– 114
(2010)
19.2 (2006)– 21.2 (2010) 1.0 (2006)–
1.0 (2010)
- - -
2 Hoer et al.
[41]
0.54 - - - - - -
3 Hoffmann
et al.[40] �
1.39 - - 2.086��� - - Opioid prescribed most:
Fentanyl, 40.8% of DDD
4 Ihle et al. [45] 3.31 (2000)– 4.46
(2009)
- - 2000–2009:
+67%
- 82.7/17.3 (2000)
79.4/20.6 (2009)
DDD increased by
+122.6%
5 Jacob et al.
[43]
1.6 - - - - - -
6 Lindena et al.
[46] �
0.1 - - - - 60.2/40.8 -
7 Marschall
et al. [8] ����
- - 1.3�� - 58 - Insureds with high-dose
opioids among LTOT:
15.5%
8 Schubert et al.
[13]
3.31 (2000)– 4.53
(2010)
(+37%)
- - 2000–2010:
+ 53.4%
- 80.6/19.4 (2000)
76.7/23.3 (2010)
DDD increased by
+109%
9 Sorge
et al. [47] �
0.057 (1985)
0.075 (1988)
- - - - - Total DDD Germany: 56
million (1985)– 62
million (1988)
10 Werber et al.
[14]
5.7 (2006)– 5.9
(2009)
(+3.5%)
- - - - - DDD CCP: 6,282,000
(2006), 8,087,000 (2009)
DDD CNCP: 27,398,000
(2006), 32,391,000
(2009)
11 Willweber-
Strumpf
et al. [44] �
0.059 - - - - 17.76/82.24 -
12 Zenz et al.
[42]
1.9 ����� - - - - - -
� Strong opioids only
�� Prevalence of LTOT prescriptions for CNCP among all insureds
��� DDD per insured, not per user
���� LTOT only
����� Strong opioids for cancer pain only
https://doi.org/10.1371/journal.pone.0221153.t005
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osteoporosis (9.3%). The prevalence of strong opioid prescriptions among insureds increased
for both, non-cancer (2006: 0.75%, 2009: 1.01%, +34.7%) and cancer patients (2006: 0.33%,
2009: 0.42%, +27.3%) [14]. Marschall et al. [8] calculated prevalence of opioid use for non-can-
cer patients only. Despite including different medical conditions in their analysis as potential
confounders, they only described the most frequent orthopaedic diagnoses associated with
LTOT (low back pain, osteoarthritis). In addition, they also found nearly half of their sample
to be diagnosed with somatoform pain disorder [8].
Zenz et al. [42] investigated the prevalence of strong opioid prescriptions for cancer patients
and did not include numbers for non-cancer patients in findings.
Discussion
The reviewed literature suggests an increase in the number of patients with opioid prescrip-
tions and DDD of opioids per recipient in Germany over time [13–15, 45, 47]. Moreover, dur-
ing the last decade, the majority of opioid prescription seems to have been used for patients
with non-cancer pain, although the German guideline does not recommend opioids as a first-
line therapy for CNCP [13, 31, 38, 45]. The use of prescription opioids tends to be more com-
mon in older people, women and in the north of Germany [8, 13–15, 40, 45]. Fentanyl seems
to be the most prescribed strong opioid in outpatient settings in Germany despite not being
the first-line choice for chronic pain conditions [14, 40, 41]. Globally, a pronounced trend
towards strong opioids—particularly in non-cancer patients—is described [13, 14]. All data
published before 2000 suggests insufficient pain management using opioids [42, 44, 46, 47].
Although studies’ findings show an increase in terms of patients with opioid prescriptions and
DDD of opioids per recipient during the last decade, none of the more recent studies show
Fig 3. Comparison of opioid prescription prevalence over time.
https://doi.org/10.1371/journal.pone.0221153.g003
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signs for an opioid epidemic in Germany [8, 50]. In fact, despite a 30% increase between 2012–
15, drug-related deaths in Germany (74% of which concern opioids) have remained relatively
stable since 2006 overall [51].
Strengths and limitations
This review has not been registered through PROSPERO prior to publication and thus, the
risk of other reviews addressing the same question being published simultaneously cannot be
ruled out. Only two databases were searched in order to find relevant studies for this review
which reflects a potential selection bias. Searches were limited to titles and abstracts only. Rele-
vant studies in which opioids were mentioned as a subgroup of pain medication may have
been missed. Although no exclusion criteria were defined regarding time, no studies were
found dating back to before 1990. This may be due to there being no register of older studies
in the databases, but also to the political division of Germany that remained until 1989.
The unavailability of full-texts of possibly relevant studies may also be source of selection
bias. The comparability of findings is limited by different case ascertainment strategies and the
different regions within Germany studies are referring to. Also, this review is affected by publi-
cation bias since it exclusively relies on published papers. An overview of the strengths and
limitations of data included in this review is presented in Table 6.
Fig 4. Geographical distribution of study population including prevalence of opioid prescription in % [49].
https://doi.org/10.1371/journal.pone.0221153.g004
Opioid prescription patterns in Germany
PLOS ONE | https://doi.org/10.1371/journal.pone.0221153 August 28, 2019 13 / 20
Although insurance data have advantages for researchers such as large sample sizes that
yield statistically significant results, there are several methodological flaws related to the use of
such data in health research. Firstly, it is often pointed out that insurance data is primarily col-
lected for financial purposes (instead of research purposes) which makes it somewhat unsuit-
able for thoroughly exploring important health-related research questions (e.g. prevalence
estimates, risk factors, aetiology, and treatment outcomes). Furthermore, results of studies based
on insurance data are not likely to be generalisable to a wider population (external validity) due
to study samples not being representative of the population of interest [52]. With most studies
included in our review (8 out of 12) analysing data from statutory health insurances (gesetzliche
Krankenversicherung—GKV)—representing only 90% of the German population—certain pop-
ulation groups are not included in datasets and analyses, which introduces selection bias. There-
fore, no generalisability of our results is given for the group of privately insured Germans,
namely civil servants, freelancers and most citizens earning annual salaries above a certain
threshold (€57,600 per year in 2017). Lastly, the use of insurance claims data incorporates a bias
in terms of (over)estimation of the prevalence of opioid use, since it does not provide informa-
tion on how much of the opioids prescribed were actually consumed by patients. Only four stud-
ies—published before 2000—reported total numbers of prescriptions within their samples and
additionally, prescriptions per person [42, 44, 46, 47]. Eight papers only accounted for patients
Fig 5. Prescription quantities of high-potency opioids in DDD/100 insureds according to postcode regions in
2011. (Hoffmann et al.) [40].
https://doi.org/10.1371/journal.pone.0221153.g005
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with at least one prescription, which may be a possible underestimation of the prevalence [8, 13–
15, 40, 41, 43, 45].
A further limitations of this review is the observed heterogeneity in study methodology.
This is reflected by big differences in sample selection between reviewed studies. Only three
studies used randomisation in their sample selection process [8, 13, 45] and only two papers
checked whether chosen samples were representative of the German population [8, 14]. Schu-
bert et al. and Ihle et al. [13, 45] standardised their calculated annual treatment prevalence to
the population of Germany on 31 December of 1999 and the previous year respectively. Buth
et al. [15] chose the entire population of all four states included in the sample as a denominator
for their prevalence calculations and extrapolated their results since only 88% of the popula-
tion is covered by their data source. One study excluded two patients from the sample after pri-
mary analysis due to treatment for opioid dependence rather than for pain conditions [44].
One study did not describe their sample selection process [46].
Six studies referred to the entire German population [8, 14, 40, 41, 43, 46]. Four of them
used data from only one statutory health insurance [8, 14, 40, 41]. A sampling bias could be
seen in the six studies using data from specific regions within Germany, which makes it diffi-
cult to draw inferences about the German population as a whole [13, 15, 42, 44, 45, 47]. None
of the studies checked for representativeness of the samples selected regarding age or sex
(selection bias).
Furthermore, case ascertainment varied greatly. Five studies calculated prevalence of strong
opioid use, with only Zenz et al. solely including cancer patients [40, 42, 44, 46, 47]. Marschall
et al. [8] solemnly referred to CNCP patients with LTOT and Werber et al. [14] only
Fig 6. Proportion of cancer and non-cancer patients within the group of patients with opioid prescriptions. Confidence
intervals not given.
https://doi.org/10.1371/journal.pone.0221153.g006
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investigated chronic pain conditions. Five studies reported the prevalence of all opioid pre-
scriptions regardless of opioid classification or type of pain [13, 15, 41, 43, 45]. However, opi-
oids included in these studies differed: two studies excluded codeine, methadone and
levomethadone [13, 45], one included all opioids [14], and one only excluded methadone and
polamidone [8]. One study additionally included the use of benzodiazepines and z-substances
in the analysis [15]. Jacob et al. [43] did not investigate opioid use but researched the use of
pain medication in the UK, Germany and France in general. Hoer et al. [41] primarily
included all insureds with opioid prescriptions in their study but focused on the prevalence of
transdermal and oral opioids.
As a result of the diversity in terms of study design and outcomes, findings from most of
the reviewed studies are temporally and geographically fragmented. Therefore, they cannot be
considered as representative of the German general outpatient population, nor be generalised
to a particular period of time or geographical area. Nevertheless, they bring up some evidence
allowing us to create a—so far missing—first summary of opioid prescribing practices in
Germany.
Table 6. Strengths and limitations of the included data.
Strengths Limitations
• Studies in German and English were included in this
review
• Most studies used very large study samples (only four
studies [13, 44, 45, 47] had samples of less than 500,000
patients)
• All studies used the same opioid classification system
(WHO)
• All studies except one [8] used the prevalence of
patients with opioid prescriptions as a primary outcome
measure
• The majority of the data derived from statutory health
insurances which means that there is no recall or
interviewer bias involved in the included retrospective
studies
• Only three studies randomised their study sample to
reduce confounding [8, 13, 45]
• All of the included studies were retrospective
• There is no national surveillance data on opioid
consumption in Germany; studies rely solely on other
data sources—mostly registries—which were not designed
for study purposes in the first place and cannot represent
the German population in its entirety (selection bias)
• Eight studies [8, 13, 14, 40, 41, 44, 45, 47] had one
statutory health insurance each (some of them the same)
as primary data source to draw inferences about the
German population which is a potential selection bias
since it does not account for privately insured patients,
private prescriptions & patients of other insurances,
patients changing health insurances
• Two studies [13, 45] got their data from exactly the same
study sample and used the same methodology but
reported results for different years
• Only six studies referred to all of Germany [8, 14, 40, 41,
43, 46]; four studies referred to regions [13, 15, 42, 45]
and two studies to cities [44, 47] within Germany to draw
inferences about the German population (lack of
generalisability)
• Different opioid classes and sometimes even different
opioids within one opioid class were included/excluded
which makes comparison between studies difficult and
might be the source of a potential misclassification bias
• Only two studies [8, 13] stated confidence intervals for
their prevalence which makes it the interpretation of the
differences difficult
Eight studies [13–15, 41, 42, 45, 46] analysed data for
more than one year but only four of the studies [13, 15,
45, 46] reported trends over time
• All studies except one [8] looked at patients with at least
one prescription of opioids to calculate prevalence of
opioid prescription which is a potential underestimation
of opioid use
• Only two studies [8, 43] stated their inclusion criteria
regarding age groups
• Only three studies [8, 43, 45] reported the sex of patients
included in the study
https://doi.org/10.1371/journal.pone.0221153.t006
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Conclusion
Over the last decades, pain management has been significantly improved in developed coun-
tries, notably due to a wider availability of opioid pain relievers for CNCP treatment [53]. On
average, the prevalence of opioid prescriptions grew by almost 110% between 2002 and 2007
across the OECD. In Europe, changes in opioid consumption have been mainly characterised
by increasing use of tramadol, fentanyl and oxycodone. The rapid growth of the opioid market,
combined with described changes in prescription patterns, led to opioid use being on the
agenda of public health professionals worldwide [54].
In this context, the aim of this review was to assess and compare the evidence on opioid pre-
scription in Germany, to discuss relevant literature and to evaluate trends in prescribing and
potential differences in prescription patterns.
Despite aforementioned limitations and the restricted comparability between studies, it can
be stated that both, number of opioid prescriptions overall and number of people receiving
opioid treatment, have increased during the last decades. Findings from our review are there-
fore consistent with previous research in the field, according to which Germany is the second
largest consumer of opioid pain relievers in Europe behind the United Kingdom and ahead of
Spain [55]. Most opioid prescriptions nowadays involve strong opioids and are given out to
patients with non-cancer pain, with Fentanyl being the most prescribed strong opioid in out-
patient settings. However, even though patterns of opioid prescription follow similar trends
than other developed countries, there are no signs of an opioid epidemic in Germany so far,
especially considering that the number of opioid-related deaths has remained stable since 2006
[50, 51]. Therefore, this review could currently not find a need for urgent health policy inter-
ventions regarding opioid prescription practices. However, critical gaps in the literature
remain and more well-conducted data collection and research is needed to make more reliable
judgements.
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